1-2 of 2
Graham P. Taylor, MD DSc
Close
Sort by
Journal Articles

HTLV-1 Proviral Load after Two Months' Treatment with Anti-CCR4 Monoclonal Antibody Mogamulizumab Predicts a Molecular Response to Disease and Durable Clinical Remission in Leukaemic Subtypes of Adult T-Cell Leukaemia/Lymphoma

Lucy B Cook, MB BS, PhD, Aileen G Rowan, PhD, Maria Antonietta Demontis, PhD, Sasha Marks, MB BS, PhD, Charles R. M. Bangham, Paul Fields, MD PhD, Graham P. Taylor, MD DSc
Journal: Blood
Blood (2016) 128 (22): 5356.
https://doi.org/10.1182/blood.V128.22.5356.5356
Published: 2016
Journal Articles

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator's Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival

Adrienne Phillips, MD, Paul Fields, MD PhD, Olivier Hermine, MD PhD, Juan Carlos Ramos, MD, Brady E Beltran, MD, Juliana Pereira, MD PhD, Carlos Brites, MD, Farooq Ahmad Wandroo, MD FRCPath, FRCP, Michael Lill, MD, Tatyana A Feldman, MD, Luis Casanova, MD, Murali Janakiram, MD, Jean-Come Meniane, MD, Ahmed Sawas, MD, Lucy B Cook, MB BS, PhD, Michael R. Kurman, MD, Joyce George, MS, Karen Dwyer, BA, Mollie Leoni, MD, Kevin Conlon, MD, Graham P. Taylor, MD DSc, Jason Gonsky, MD PhD, Steven M. Horwitz, MD
Journal: Blood
Blood (2016) 128 (22): 4159.
https://doi.org/10.1182/blood.V128.22.4159.4159
Published: 2016